TY - JOUR
T1 - The Lancet Child & Adolescent Health Commission on the future of neonatology
AU - De Luca, Daniele
AU - Modi, Neena
AU - Davis, Peter
AU - Kusuda, Satoshi
AU - de Wildt, Saskia N.
AU - Keszler, Martin
AU - Abbas-Hanif, Allyah
AU - Juul, Sandra E.
AU - Turner, Mark
AU - Pillow, J. Jane
AU - Robertson, Nikki
AU - Sanchez-Luna, Manuel
AU - Tingay, David G.
AU - Benachi, Alexandra
AU - Bustreo, Flavia
AU - Ianiro, Gianluca
AU - Hanson, Mark
AU - Deprest, Jan
AU - De Coppi, Paolo
AU - van den Hoogen, Agnes
AU - Tarnow-Mordi, William
AU - Zanin, Anna
AU - Oei, Ju Lee
AU - Zhang, Huayan
AU - Lara-Diaz, Victor Javier
AU - Tooke, Lloyd
AU - Flori, Heidi
AU - Ricciardi, Walter
AU - Abman, Steven H.
N1 - Publisher Copyright:
© 2025 Elsevier Ltd
PY - 2025/8
Y1 - 2025/8
N2 - Neonatal mortality remains unacceptably high throughout the world. Survival of sick infants in their first month of life has improved over the past six decades. However, many comorbidities persist, with lifelong implications for health. The current ecosystem for research and development of drugs and medical devices to treat neonatal disorders is hindering further improvements to neonatal outcomes, especially infants born preterm or needing critical care. Innovation is lagging, and this is a public health problem characterised by multifactorial challenges in leadership, collaboration, regulation, funding, and commercial viability. The Lancet Child & Adolescent Health Commission on the future of neonatology was created to consider these challenges and design a roadmap of strategies to accelerate research and development that will innovate and improve health care for neonates. We call for regulatory agencies, governments, funders, industry partners, and clinical researchers from diverse medical fields to invest in effective pathways for drug and medical device development and to unite in responsive and dynamic collaborations with diverse patients, families, and advocacy groups whose engagement in clinical research and advocacy can help neonatologists to achieve the best science and health equity for neonates worldwide, now and in the future.
AB - Neonatal mortality remains unacceptably high throughout the world. Survival of sick infants in their first month of life has improved over the past six decades. However, many comorbidities persist, with lifelong implications for health. The current ecosystem for research and development of drugs and medical devices to treat neonatal disorders is hindering further improvements to neonatal outcomes, especially infants born preterm or needing critical care. Innovation is lagging, and this is a public health problem characterised by multifactorial challenges in leadership, collaboration, regulation, funding, and commercial viability. The Lancet Child & Adolescent Health Commission on the future of neonatology was created to consider these challenges and design a roadmap of strategies to accelerate research and development that will innovate and improve health care for neonates. We call for regulatory agencies, governments, funders, industry partners, and clinical researchers from diverse medical fields to invest in effective pathways for drug and medical device development and to unite in responsive and dynamic collaborations with diverse patients, families, and advocacy groups whose engagement in clinical research and advocacy can help neonatologists to achieve the best science and health equity for neonates worldwide, now and in the future.
UR - https://www.scopus.com/pages/publications/105008974138
U2 - 10.1016/S2352-4642(25)00106-3
DO - 10.1016/S2352-4642(25)00106-3
M3 - Review article
AN - SCOPUS:105008974138
VL - 9
SP - 578
EP - 612
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
IS - 8
ER -